Previous Article | Next Article ![]()
Journal of Virology, November 2001, p. 10950-10957, Vol. 75, No. 22
New York VA Medical Center and New York
University School of Medicine, New York, New York
100101; Department of Immunology,
Chelsea and Westminster Hospital, London SW10 0NH, United
Kingdom2; Henry M. Jackson Foundation
and Division of Retrovirology, Walter Reed Army Institute of Research,
Rockville, Maryland 208503; Partners
AIDS Research Center, Massachusetts General Hospital, Boston,
Massachusetts 021144; and Gladstone
Institute of Virology and Immunology, University of California, San
Francisco, California 941415
Received 13 March 2001/Accepted 16 August 2001
Human immunodeficiency virus (HIV)-specific CD4 T-cell responses,
particularly to the envelope glycoproteins of the virus, are weak
or absent in most HIV-infected patients. Although these poor responses
can be attributed simply to the destruction of the specific CD4 T cells
by the virus, other factors also appear to contribute to the
suppression of these virus-specific responses. We previously showed
that human monoclonal antibodies (MAbs) specific for the CD4 binding
domain of gp120 (gp120CD4BD), when complexed with gp120,
inhibited the proliferative responses of gp120-specific CD4 T-cells.
MAbs to other gp120 epitopes did not exhibit this activity. The present
study investigated the inhibitory mechanisms of the
anti-gp120CD4BD MAbs. The anti-gp120CD4BD MAbs
complexed with gp120 suppressed gamma interferon production as well as
proliferation of gp120-specific CD4 T cells. Notably, the T-cell
responses to gp120 were inhibited only when the MAbs were added to
antigen-presenting cells (APCs) during antigen pulse; the addition of
the MAbs after pulsing caused no inhibition. However, the
anti-gp120CD4BD MAbs by themselves, or as MAb/gp120
complexes, did not affect the presentation of gp120-derived peptides by
the APCs to T cells. These MAb/gp120 complexes also did not inhibit the
ability of APCs to process and present unrelated antigens. To test
whether the suppressive effect of anti-gp120CD4BD
antibodies is caused by the antibodies' ability to block gp120-CD4
interaction, APCs were treated during antigen pulse with anti-CD4 MAbs.
These treated APCs remained capable of presenting gp120 to the T cells.
These results suggest that anti-gp120CD4BD Abs inhibit
gp120 presentation by altering the uptake and/or processing of gp120 by
the APCs but their inhibitory activity is not due to blocking of gp120
attachment to CD4 on the surface of APCs.
0022-538X/01/$04.00+0 DOI: 10.1128/JVI.75.22.10950-10957.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
Inhibition of Human Immunodeficiency Virus Type 1 gp120 Presentation to CD4 T Cells by Antibodies Specific for the CD4
Binding Domain of gp120
*
Corresponding author. Mailing address: VA Medical
Center, 423 E. 23rd St., Room 18-124 North, New York, NY 10010. Phone:
(212) 263-6769. Fax: (212) 951-6321. E-mail:
hioec01{at}med.nyu.edu.
This article has been cited by other articles:
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»